Quanterix Corporation reported a solid Q3 2025 performance with $40.2 million in revenue, marking a 12% year-over-year increase and demonstrating effective integration post-Akoya acquisition.

• Achieved $67 million of the targeted $85 million in cost synergies from the Akoya acquisition within just over three months.
• Instrumentation and accelerator revenues showed sequential growth, signaling potential market stabilization.
• Invested approximately $27 million in R&D, underlining commitment to innovation, particularly in Alzheimer's diagnostics.
• On track to maintain a strong cash position with projected year-end cash of around $120 million and no debt.
• Early success in commercial synergy with growing interest in multimodal biomarker strategies among customers.